Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 17:10:57-61.
doi: 10.2147/HIV.S140799. eCollection 2018.

HIV seroconversion during pregnancy and the need for pre-exposure prophylaxis (PrEP)

Carmen D Zorrilla  1 , Fiorella Reyes Báez  1 , Karolyn González Colón  2 , Jessica Ibarra  2 , Iris García  2 , Ana M Mosquera  2
Affiliations

HIV seroconversion during pregnancy and the need for pre-exposure prophylaxis (PrEP)

Carmen D Zorrilla et al. HIV AIDS (Auckl). .

Abstract

The reduction in the mother-to-infant transmission of HIV has been among the early successes of care and treatment of women living with HIV. Prenatal HIV counseling and testing, the availability of diverse antiretroviral therapies, elective cesarean section, and the use of formula milk have significantly reduced the mother-to-infant transmission in the USA and Europe. We are presenting two cases of seroconversion during pregnancy, identified during labor and delivery, of women who received risk reduction counseling and serial HIV testing during pregnancy. Because there are no guidelines for (or easy access to) the use of pre-exposure prophylaxis (PrEP) in pregnancy, they were offered other strategies for prevention including risk reduction counseling, condoms, and serial HIV testing. These cases support the use of PrEP during pregnancy. Both infants were negative and the women are currently receiving long-term highly active antiretroviral therapy. One of them recently delivered another infant. After these two women seroconverted, we decided to offer PrEP to all pregnant women presenting for care who report having an HIV positive partner. During the period 2012-2014, we treated ten HIV negative pregnant women who were partners of HIV positive men. Since 2015, we have seen 20 pregnant women in HIV discordant relationships. Of those, seven received PrEP. No seroconversions have been observed among the pregnant women on PrEP. Although small numbers, seroconversion during pregnancy was observed in two of 13 (15%) of the pregnant women in HIV-discordant relationships seen in our clinic, excluding those treated with PrEP. Given the safety data and experience with tenofovir and emtricitabine among pregnant women living with HIV, we believe PrEP should be offered in pregnancy and that guidelines should reflect this option as an additional strategy to reduce risks during pregnancy and to further reduce infant HIV transmission risk.

Keywords: HIV; HIV seroconversion; PrEP; pregnancy.

PubMed Disclaimer

Conflict of interest statement

Disclosure Dr Zorrilla receives research funding from the National Institutes of Health: NIAID, NICHD and NIMH; from the US Department of Health and Human Services: HRSA HIV/ AIDS Bureau/Ryan White Program and from the following companies: Gilead, BMS and GSK. The other authors report no conflicts of interest in this work.

References

    1. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011. AIDS. 2014;28(7):1049–1057. - PubMed
    1. Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS. 2011;25(15):1887–1895. - PMC - PubMed
    1. Dinh TH, Delaney KP, Goga A, et al. Impact of maternal HIV sero-conversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4–8 weeks postpartum in South Africa 2011–2012: a national population-based evaluation. PLoS One. 2015;10(5):e0125525. - PMC - PubMed
    1. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis for all populations. AIDS. 2016;30(12):1973–1983. - PMC - PubMed
    1. World Health Organization . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2016. [Accessed February 26, 2018]. Available from: http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?.... - PubMed